Maze Therapeutics, Inc.

MAZE

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Driehaus Capital Casdin Capital Eventide Asset Management

Position Trend

Feb 13, 2026

$13.4M

1 fund

Feb 17, 2026

$47.1M

2 funds

+251% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 378,015Value: $15.7M

# Signal Note: Driehaus Growth Entry into MAZE Driehaus Capital's $15.7M initiation suggests conviction in Maze's pipeline, likely centered on ulrogepant (migraine), which is progressing toward potential regulatory catalysts in 2024-2025. The growth-focused investor's entry indicates confidence in either near-term approval probability or competitive positioning in the migraine market, where GLP-1 uptake has reshaped demand dynamics. Position sizing (~378K shares) reflects meaningful but not outsized conviction, consistent with early-stage biotech risk parameters.

Casdin CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

BBIO3 funds RNA3 funds ALNY3 funds RVMD3 funds SRRK3 funds AXON2 funds NVDA2 funds VEEV

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Casdin Capital Initiates $31.4M Position in Maze Therapeutics** Casdin's entry signals confidence in Maze's platform for rare genetic diseases, particularly its lead program in ALGS (Alagille syndrome), which targets NOTCH2 stabilization—a novel mechanism in a ~5,000 patient U.S. market with limited approved options. The $31.4M stake likely reflects conviction ahead of upcoming clinical milestones, potentially including Phase 2 data readouts expected in 2024-2025 that could validate target engagement and clinical benefit in a disease with significant unmet need.